Sodium thiosulfate: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[Antidote]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: | *Routes of Administration: IV | ||
*Common Trade Names: | *Common Trade Names: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Cyanide toxicity]]=== | ===[[Cyanide toxicity]]=== | ||
*Adult: 12.5 g IV | *Adult: 12.5 g IV (after giving [[sodium nitrite]] 300 mg) | ||
===Prophylaxis during nitroprusside infusion=== | ===Prophylaxis during nitroprusside infusion=== | ||
| Line 15: | Line 15: | ||
===[[Cyanide toxicity]]=== | ===[[Cyanide toxicity]]=== | ||
*Pediatric: 400 mg/kg IV | *Pediatric: 400 mg/kg IV | ||
*Per micromedex: 412.5 mg/kg or 7 g/m(2) administered at a rate of 0.625 to 1.25 g/min IV | |||
===Prophylaxis during nitroprusside infusion=== | ===Prophylaxis during nitroprusside infusion=== | ||
| Line 21: | Line 22: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug pregnancy categories|Pregnancy Rating]]: C | *[[Drug pregnancy categories|Pregnancy Rating]]: C | ||
*Lactation risk: | *Lactation risk: Infant risk cannot be ruled out | ||
*Renal dosing: not established | |||
*Hepatic dosing: not established | |||
* | |||
==Indications== | ==Indications== | ||
| Line 45: | Line 41: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 80 min | ||
*Metabolism: | *Metabolism: Liver | ||
*Excretion: | *Excretion: Renal | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Sulfur donor that promotes conversion of cyanide to thiocyanate | |||
==Comments== | ==Comments== | ||
*Whereas the nitrites have adverse effects, sodium thiosulfate is non-toxic | *Whereas the nitrites have adverse effects, sodium thiosulfate is non-toxic | ||
==See Also== | ==See Also== | ||
*[[Cyanide toxicity]] | *[[Cyanide toxicity]] | ||
*[[Sodium nitrite]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 16:11, 17 May 2017
Administration
- Type: Antidote
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names:
Adult Dosing
Cyanide toxicity
- Adult: 12.5 g IV (after giving sodium nitrite 300 mg)
Prophylaxis during nitroprusside infusion
- Add 10 mg sodium thiosulfate for each 1 mg of nitroprusside
Pediatric Dosing
Cyanide toxicity
- Pediatric: 400 mg/kg IV
- Per micromedex: 412.5 mg/kg or 7 g/m(2) administered at a rate of 0.625 to 1.25 g/min IV
Prophylaxis during nitroprusside infusion
- Add 10 mg sodium thiosulfate for each 1 mg of nitroprusside
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: not established
- Hepatic dosing: not established
Indications
- Acute cyanide toxicity
- Smoke inhalation with potential for cyanide exposure
- Prophylaxis during nitroprusside infusions
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- Burning sensation and muscle cramping from infusion
Pharmacology
- Half-life: 80 min
- Metabolism: Liver
- Excretion: Renal
Mechanism of Action
- Sulfur donor that promotes conversion of cyanide to thiocyanate
Comments
- Whereas the nitrites have adverse effects, sodium thiosulfate is non-toxic
See Also
References
- Olson, K. Poisoning and Drug Overdose, 1999.